Navigation Links
PURE Bioscience Board Appoints John J. Carbone, MD to Board of Directors

SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that John J. Carbone, MD has been appointed to the Board of Directors. Dr. Carbone fills the vacancy left by the resignation of Murray Gross on February 13, 2009.


Michael L. Krall, President/CEO and Chairman of PURE Bioscience, commented, "We believe that SDC has tremendous potential in numerous healthcare applications, and we are extremely pleased and honored to have someone with Dr. Carbone's experience and leadership on our Board. Dr. Carbone's guidance will be a great benefit to PURE in our efforts to fully develop a market for SDC in healthcare."

Dr. Carbone stated, "I have always been fascinated with new technologies in my field, and I think that the SDC molecule presents intriguing and promising opportunities in medicine. I'm looking forward to supporting the research for and commercialization of SDC in medicine."

Dr. Carbone is a Board Certified Orthopedic Surgeon and a Fellow of the American Academy of Orthopedic Surgeons. Since 2004 he has served as the Director, Orthopedic Spine Services at Harbor Hospital in Baltimore, MD.

Dr. Carbone specializes in the design and use of orthopedic implants and surgical instruments as well as the biomechanics and clinical outcomes of spinal surgery. Currently, he holds several patents for orthopedic prosthetic devices and implants and is a consulting surgeon to the National Aquarium in Baltimore, MD. Dr. Carbone specializes in the treatment of all types of spinal pathology from degenerative cervical and lumbar disease to reconstructive deformity, failed spine surgery syndrome, and minimally invasive spinal surgery.

Dr. Carbone received a bachelor's degree in engineering from The United States Merchant Marine Academy in 1983. He then served as a marine engineer for Military Sealift Command until 1988. He received an honorable discharge as a lieutenant in the United States Naval Reserve in 1993. He received his medical degree from the University of Maryland School of Medicine in 1992. He completed his orthopedic residency training at The Johns Hopkins Hospital and his reconstructive spinal surgery fellowship under Dr. John Kostuik. Concurrent with his early medical career, Dr. Carbone also served in senior executive positions at two orthopedic research and design companies.

Dr. Carbone's combination of medical and engineering talents has led to a distinguished career in orthopedics research and design. His primary research focuses on the biomechanical design and use of orthopedic implants in spinal fusion.

Dr. Carbone serves on the PURE Bioscience Board as an independent director and a member of the audit committee. Dr. Carbone is not, and has not been for the past three years, employed by the Company or by any parent or subsidiary of the Company and has not accepted any payments from the Company or any parent or subsidiary of the Company during the current or any of the past three fiscal years. No family relationships exist between Dr. Carbone and PURE Bioscience, its directors or officers.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    PURE Investor Contact:               PURE Media Contact:
    Paul G. Henning, Vice President      Michael Gallo
    Cameron Associates                   Gutenberg Communications
    (212) 554-5462                       (212) 239-8594      

SOURCE PURE Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
2. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
3. Pressure BioSciences, Inc. to Present at the EdgeWater Research Partners Spring 2009 Micro/Small-Cap Investor Conference
4. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
5. INVO Bioscience Completes Reverse Merger
6. Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
7. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
8. Pressure BioSciences, Inc. Announces Completion of Private Placement
10. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Genetic testing for mutations ... the identification of more couples at risk of having ... presented today at the 2015 American Society of Human ... in Baltimore, Maryland . The study ... (NYSE: DGX ) are presenting at the conference ...
(Date:10/8/2015)... DURHAM, N.C. and WAYNE, Pa. ... leading management and technology consulting firm, has announced the ... Pennsylvania , majoring in a ... awarded over a two-year period. In addition, the selected ... industry through mentoring with Clarkston Consulting and participation in ...
(Date:10/8/2015)... BALTIMORE, Maryland , October 8, 2015 /PRNewswire/ ... .   --> Goldman ... specializing in the small cap and microcap sectors, ... sponsored research report on PharmaCyte Biotech, Inc. (OTCQB ... company focused on developing and preparing treatments for ...
(Date:10/8/2015)... , Oct. 8, 2015 The 2015 Nobel Prize ... University of Texas at Dallas. Aziz Sancar , who ... Dallas in 1977, is one of three scientists ... continuously monitor and repair damaged DNA on a molecular level.  ... and cell biology from UT Dallas in ...
Breaking Biology Technology:
... Madison, Wis. Paragon Development Systems (PDS) ... expand its presence in Madison into a new building. , ... Madison designs, builds and manages IT infrastructure and services ... vice president of IT infrastructure services, is responsible for restructuring ...
... and undergraduate degree were minted at the University of ... North American operations, the company said on Wednesday. He ... headquartered in Massachusetts, provides "enterprise service bus" technology to ... Wisconsin Department of Administraiton. , ,Though its definition is ...
... Madison, Wis. Massachusetts-based Genzyme Corp. said ... International , a University of Wisconsin-Madison biotech spinoff, for $600 ... company with annual revenues of more than $2 billion and ... the third quarter. , ,Both companies recently reported healthy quarterly ...
Cached Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... September 28, 2015 According to ... & Software), Product (Scanner & Others), Application (Access Control ... & Others) & Geography Global - Forecast to 2020", published ... reach USD 3627.90 Million by 2020, at a CAGR ... Browse 65 market data T ables and ...
Breaking Biology News(10 mins):
... tomato breeders and ketchup fans something to cheer about, ... colleagues at the Hebrew University in Israel have identified ... increase yield. The yield-boosting power of this gene, which ... of tomato, and crucially, across a range of environmental ...
... - A new minimally invasive surgery to correct a ... -- was demonstrated Friday at an international conference attended by ... Germany, Spain and Russia. Technically known as pectus carinatum, ... the patient,s chest the appearance of the breast of a ...
... how a new research program may shed light on how ... subject of a public event that will discuss the findings ... Influence on Human Evolution. Several members of the committee ... be carried out in the next 10 to 20 years ...
Cached Biology News:
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
... peptide transporter 2 (APT2) ... transporter PSF2) (Peptide supply ... transporter involved in antigen ... Antigen: ...
... Nabeta2. The epitope specific for ... any other known proteins.,SPECIES REACTIVITIES: ... work on human because the ... (17/19 residues). Reactivity with other ...
Biology Products: